Anti-Depressant Drugs, Devices and Therapies Market Analysis 2019-2027

GLOBAL ANTIDEPRESSANTS, DRUGS, DEVICES AND THERAPIES MARKET

FORECAST 2019-2027

• The global anti-depressant drugs, devices and therapies market is anticipated to grow at a CAGR of 1.81% CAGR during the year 2019-2027. • The revenue generated by the market is expected to increase from $15,569 million in 2018 and reach $18,183 million by 2027. • The antidepressant drugs, devices, and therapies market is primarily driven because of factors such as a shift in the geriatric population size, growing awareness about depression as a medical disorder and the surge in sales of antidepressants in the past few years.

• The market is segmented into types of antidepressants drugs, types of devices and the types of therapies for further simplification and a thorough study of the services and trends followed by the market players.

• The high cost for depression therapies, patent expiration faced by the companies for several drugs, coupled with the delay in product launches are majorly restraining the progression and expansion of the market.

• However, with the rising awareness about depression being a medical condition, the market is expected to show a huge promise during the forecasted years.

• Moreover, the rapid ongoing research and development activities for the drug discovery in the global depressant market are expected to find new, cost-effective and impactful antidepressant drug.

The global anti-depressant drugs, devices and therapies market is anticipated to grow at a CAGR of 1.81% CAGR during the year 2019-2027.

The North American region is one the largest antidepressants drugs, devices, and therapies by diagnosed patients, devices manufacturers and establishment of several psychiatrists and psychologists that have contributed to the growth of the market at a CAGR of 1.27% during the forecasting years of 2019-2027.

The antidepressants drugs, devices and therapies m arket in Europe is undergoing an intensified growth of 1.77% CAGR during the forecasting years of 20192027.

The Asia Pacific is currently ranked third in terms of revenue from the depression drugs and devices market, where the expected growth rate of the antidepressants drugs, devices, and therapies market is 3.32% CAGR during the forecasting years of 2019-2027.

Branded drug manufacturing companies generally invest in R&D and produce drugs in-house. Some of the major blockbuster drugs produced by branded drug companies are H. Lundbeck AS, Boehringer Ingelheim GmbH, Allergan PLC, Mayo Clinic, Brainsway, Pfizer, Neuronetics, Abbot Laboratories, F. Hoffmann-La Roche Ltd., Eli Lilly, and Company and GlaxoSmithKline. They have reaped billions of dollars by having